Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455844 | 0.76 | TSHR (0.39) | ATRCNR2CNR1TSHRALDH1A1 | |
| SCHEMBL22499043 | 0.65 | RXRA (0.47) | ATRALDH1A1POLB | |
| SCHEMBL31393181 | 0.64 | RXRA (0.43) | ATRALDH1A1POLB | |
| SCHEMBL20604869 | 0.63 | SMN1; SMN2 (0.45) | CNR2CNR1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL22499208 | 0.62 | ATR (0.43) | ATR | |
| SCHEMBL13190181 | 0.62 | WNT1 (0.42) | CNR2CNR1TSHRALDH1A1POLB | |
| SCHEMBL717349 | 0.61 | PIK3CG (0.41) | ATR | |
| SCHEMBL22499231 | 0.61 | RXRA (0.45) | ATRALDH1A1POLB | |
| SCHEMBL2594585 | 0.60 | OPRK1 (0.43) | — | |
| SCHEMBL457038 | 0.60 | TDO2 (0.47) | TSHRALDH1A1HTTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | ATR 784/4885CNR2 4596/4885CNR1 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.